People News: Novartis, Afferent Pharmaceuticals and Axon
Afferent Pharmaceuticals hired Bruce McCarthy, MD, as CEO. He had been an industry consultant, serving as head of development and chief medical officer for several start-up companies. Dr. McCarthy's previous roles include a succession of senior positions at Pfizer, including VP, neuroscience development. Before Pfizer he worked for Abbott Laboratories. Afferent's lead neuroscience compound, AF-219, is in clinical testing.
Healthcare consulting firm Axon hired Mario Nacinovich as managing director of Axon US. He is based in New York and will report to Ralph Sutton, Axon's managing partner based in London. Axon is the international healthcare operation of National Public Relations. Prior to joining the firm, Nacinovich was VP of strategic planning and business development at medical-education firm QD Healthcare Group. His previous roles included chief growth officer for Caudex Medical and co-CEO and co-founder of Fission Communications and VP of strategic planning, director of business development and VP of ophthalmology for Ventiv Health.